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A B S T R A C T
Purpose
The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median
survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer.
These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind,
placebo-controlled, randomized phase III trial of gemcitabine/bevacizumab versus gemcitabine/
placebo in advanced pancreatic cancer patients.
Patients and Methods
Eligible patients had no prior therapy for advanced disease, Eastern Cooperative Oncology Group
(ECOG) performance status 0 to 2, no tumor invasion of adjacent organs, and no increased
bleeding risk. The primary end point was overall survival. Patients were stratified by performance
status, extent of disease, and prior radiotherapy. Patients received gemcitabine at 1,000 mg/m2
over 30 minutes on days 1, 8, and 15 every 28 days and bevacizumab at 10 mg/kg or placebo on
days 1 and 15 every 28 days.
Results
Between June 2004 and April 2006, 602 patients were enrolled onto the study and 535 were
treated. Median overall survival was 5.8 months for gemcitabine/bevacizumab and 5.9 months for
gemcitabine/placebo (P  .95). Median progression-free survival was 3.8 and 2.9 months,
respectively (P  .07). Overall response rates were 13% and 10%, respectively. Patients with a
performance status of 0, 1, and 2 survived a median of 7.9, 4.8, and 2.4 months, respectively. The
only statistically significant differences in grades 3 and 4 toxicity occurred for hypertension (10% v
3%; P  .001) and proteinuria (5% v 1%; P  .002); venous thrombosis grade  3 was equivalent
in both arms (14% and 15%, respectively).
Conclusion
The addition of bevacizumab to gemcitabine does not improve survival in advanced pancreatic
cancer patients.
J Clin Oncol 28:3617-3622. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Pancreatic cancer has the lowest survival by stage
of any solid tumor.1 Gemcitabine, the corner-
stone of chemotherapy, has a modest impact. In
the landmark trial that compared gemcitabine to
fluorouracil, gemcitabine produced a response
rate of 5% and a median overall survival (OS) of
5.7 months.2 Although many phase II studies have
reported promising activity for various cytotoxic
and targeted agents administered with gemcitab-
ine, phase III trials of these combinations were
uniformly negative,3-10 until gemcitabine/erlo-
tinib was shown to improve survival.11 Although
the results were statistically significant, with a haz-
ard ratio (HR) of 0.82, the absolute improvement
in median OS of 5.9 months with gemcitabine
versus 6.2 months with the combination was
modest.11 Novel agents that have a greater impact
are urgently needed.
Bevacizumab (Avastin, Genentech, South San
Francisco, CA) is a recombinant humanized
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monoclonal antibody against vascular endothelial growth factor A
(VEGF-A).12 In a phase II trial of gemcitabine/bevacizumab in
metastatic pancreatic cancer patients, Kindler et al13 reported a re-
sponse rate of 21%, a median OS of 8.8 months, and a 1-year survival
of 29%. Because these data appeared promising when compared with
data for historical controls, the Cancer and Leukemia Group B
(CALGB) evaluated this regimen in a randomized phase III trial. This
article describes the results of that clinical trial; correlative studies of
angiogenic biomarkers, pharmacogenomics, and clinical economics
will be reported separately.
PATIENTS AND METHODS
Patients
Eligible patients had histologically or cytologically confirmed pancreatic
adenocarcinoma not amenable to curative surgery. Measurable disease was
not required. Prior chemotherapy for metastatic disease was not permitted.
Adjuvant chemotherapy was allowed if it did not contain gemcitabine or
bevacizumab, if it was given  4 weeks before enrollment, and if the patient
had subsequent disease progression. Prior radiation was allowed if it was
completed  4 weeks before enrollment and there was disease outside the
radiation port. An Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) 0 to 2 and adequate bone marrow (granulocytes  1,500/
L, platelets  100,000/L), renal (creatinine  1.5 mg/dL or creatinine
clearance  60 mL/min), and hepatic function (total bilirubin  1  upper
limit of normal, AST  2.5  upper limit of normal) were required. An
international normalized ratio (INR)  1.5 was required unless the patient was
on warfarin; warfarin-treated patients needed to be on a stable dose with an
INR between 2 and 3. A urine protein  1 or a 24-hour urine containing  1
g/dL of protein was required. Eligible patients were at least 18 years of age and
had a life expectancy of at least 12 weeks.
Patients could not have had a major surgery, open biopsy, or significant
traumatic injury within 28 days before registration or a fine-needle aspirate
within 7 days before registration. Patients who had significant bleeding within
6 months before registration, esophageal varices, computed tomography (CT)
scan documentation of invasion of adjacent organs, clinically significant heart
disease, or CNS disease were excluded. This protocol was reviewed by the
institutional review board of each participating center. All patients provided
written informed consent according to federal and institutional guidelines.
Treatment
Gemcitabine at 1,000 mg/m2 was given intravenously over 30 minutes on
days 1, 8, and 15 of a 28-day cycle. Bevacizumab at 10 mg/kg or placebo was
administered intravenously after gemcitabine on days 1 and 15 of each cycle.
The initial bevacizumab/placebo dose was given over 90 minutes. If no infu-
sion reaction developed, the second dose was given over 60 minutes, and
subsequent doses were given over 30 minutes. Treatment was discontinued
for progressive disease, unacceptable adverse events, or patient withdrawal
of consent.
Dose Adjustments
Dose modifications were based on toxicities within 1 day of treatment.
Adverse effects were graded according to the National Cancer Institute Com-
mon Toxicity Criteria for Adverse Events (NCI-CTCAE) version 3.0. A cycle
was not started until the absolute neutrophil count (ANC) was  1.5  109/L
and the platelet count was  100  109/L. The following dose levels of
gemcitabine were used: level 0 (1,000 mg/m2), level 1 (750 mg/m2), level 2
(550 mg/m2), and level 3 (425 mg/m2).
Within a cycle, if the ANC was between 0.5 and 0.999  109/L or the
platelet count was between 50 and 75  109/L on the treatment day, the
gemcitabine dose was reduced by one dose level. The dose was held for an
ANC  0.5  109/L or platelets  50  109/L. Febrile neutropenia required a
one-dose-level reduction of gemcitabine for subsequent cycles. Gemcitabine
was reduced by one dose level for grade 3 and held for grade 4, hepatic toxicity,
or edema.
There were no dose modifications of bevacizumab/placebo. If gemcitab-
ine was held at the beginning of a new cycle, the bevacizumab/placebo dose was
held until gemcitabine could be given. Bevacizumab/placebo was held on day
15 for platelets  50  109/L. Bevacizumab/placebo was held for bilirubin or
hepatic transaminase elevations grade  3 and was not resumed until these
were grade  2. Bevacizumab/placebo was discontinued for grade  3 bleed-
ing. For a grade 3 thrombosis or an asymptomatic grade 4 pulmonary embo-
lus, bevacizumab/placebo was held and was resumed once the patient met the
following criteria: an INR between 2 and 3 on a stable warfarin or a stable
heparin dose, no pathologic conditions that carried a high risk of bleeding, and
no bleeding grade  3 on study. Bevacizumab/placebo was discontinued for a
symptomatic pulmonary embolus or recurrent or worsening thromboem-
bolic events after it was resumed. Bevacizumab/placebo was held for persistent
or symptomatic hypertension; it was discontinued if this delayed treatment
for  4 weeks, or if grade 4 hypertension developed. A 24-hour urine was
required for proteinuria  2 on a dipstick. If the urine protein was  2 g/24
hours, bevacizumab/placebo was held until it recovered to  2 g/24 hours and
was discontinued if it was held  12 weeks. It was also discontinued for
coagulopathy grade  3, grade 4 hypersensitivity reactions, and grade 4 ad-
verse events attributable to bevacizumab, including GI perforation, intra-
abdominal hemorrhage, abscess, fistula, or wound dehiscence.
Study Evaluations
Pretreatment evaluation included a complete medical history and phys-
ical examination, complete blood count and differential (CBC), chemistry
panel, prothrombin time/INR, urinalysis, carbohydrate antigen 19-9 (CA 19-
9), pregnancy test (in women of childbearing potential), CT scan or magnetic
resonance imaging of the abdomen, and a chest x-ray or CT scan of the chest.
Plasma, urine, serum, and whole blood were obtained for research studies.
A history and physical examination were performed every 14 days. A
CBC was performed weekly. Serum chemistries were obtained every 14 days. A
urinalysis was performed every 28 days. Prothrombin time/INR was obtained
weekly only in patients receiving therapeutic warfarin. Imaging scans, CA
19-9, and plasma and urine for research studies were obtained every two cycles.
Response Criteria and Toxicity
Patients were evaluated for response according to the Response Evalua-
tion Criteria in Solid Tumors (RECIST) criteria every two cycles.14 Confirma-
tory scans were obtained at least 4 weeks following initial documentation of
objective response.
Statistical Design and Analysis
The primary end point of this study was OS, measured from trial regis-
tration until death from any cause. Patients were randomly assigned with equal
probability to gemcitabine plus bevacizumab or placebo, stratified by disease
extent (locally advanced v metastatic), ECOG performance status (0/1 v 2),
and prior radiation (no v yes). The study was powered to detect an HR of 1.35
with 90% confidence testing a two-sided log-rank hypothesis with   .05.
The design assumed an accrual rate of 20 patients per month and an additional
12 months of follow-up. The sample size was inflated approximately 10% to
compensate for patient cancellations and withdrawals for a target accrual of
590 patients. The primary efficacy analysis population was the intent-to-treat
population, defined as all patients randomly assigned, irrespective of whether
the assigned treatment was actually received. For efficacy analyses, patients
were grouped according to the treatment assigned at randomization.
Secondary end points included objective response rate and duration,
progression-free survival (PFS), and adverse events. Response was defined as
complete response (CR) or partial response (PR) per RECIST criteria.14 PFS
was measured from trial entry until time of disease progression or death from
any cause.
OS and adverse events were monitored with interim analyses during the
trial with results reported to the CALGB Data and Safety Monitoring Board
(DSMB) biannually. OS was monitored using the Lan-DeMets analog of the
O’Brien-Fleming boundaries (two-sided   .05) truncating at 2.5815 and
began when 15% of information was available. At each interim analysis, the
two-sided 99.5% CI was constructed for the observed HR, and if the targeted
HR of 1.35 was not contained in this interval, consideration was given to
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accepting the hypothesis of no difference in median survival. Bevacizumab-
specific adverse events were monitored for early stopping if the total rate
difference for grade  3 bleeding, proteinuria, or thrombosis, or grade  4
hypertension was significantly greater on the bevacizumab arm. The Lan-
DeMets analog of the Pocock boundaries15 was used to determine significance
at each test of the hypothesis. Conducting these interim analyses did not
substantially impact the overall significance level of the test.16
A stratified Cox proportional hazards regression17 was used to compare
treatment arms controlling for the stratification factors at random assignment.
Survival probability estimates were calculated using the Kaplan-Meier meth-
od.17 Rates and proportions were compared using Fisher’s exact test, where
appropriate, or a 2 approximation. SAS 9.1 (SAS Institute, Cary, NC) was
used for all statistical analyses. All analyses were based on the study database
frozen on June 9, 2009.
Patient registration, data collection, and data analysis were performed by
the CALGB Statistical Center. Data quality was ensured by careful review of
data by CALGB Statistical Center staff and the study chairperson. Quarterly
reports were submitted by the CALGB Statistical Center to the Clinical Trials
Evaluation Program of the NCI using the Clinical Data Update System.
As part of the CALGB quality assurance program, members of the Audit
Committee visit all participating institutions at least once every 3 years to
review source documents. Auditors verify compliance with federal regulations
and protocol requirements, including those pertaining to eligibility, treatment,
adverse events, tumor response, and outcome in protocols at each institution.
Such on-site medical record review was performed in 106 patients (18% of the
602 patients on this study).
RESULTS
Patient Characteristics
Between June 30, 2004, and April 14, 2006, 602 patients were
randomly assigned (302 to gemcitabine/bevacizumab, 300 to gemcit-
abine/placebo); 279 and 256 patients, respectively, received study
treatment. Of those who were randomly assigned but not treated,
52 patients withdrew consent, and no treatment information was
submitted on 15 patients (Fig 1). Eighteen patients were ineligible.
All randomly assigned patients were included in the intent-to-
treat analysis.
Patient characteristics are listed in Table 1. There were no statis-
tically significant differences between treatment arms with respect to
age, sex, PS, extent of disease, or prior radiation. Approximately 85%
of patients had metastatic disease, and 90% had a PS of 0 or 1. A slightly
greater proportion of patients on the bevacizumab arm were male
(58% v 51%); this difference was not statistically significant.
Interim Analysis
In June 2006, on the basis of a protocol-specified planned interim
analysis with 64% of the information available on OS, the CALGB
Patients randomly and blindly assigned
(ITT population; N = 602)
                Gemcitabine + bevacizumab
Allocated to intervention (n = 302)
Received allocated intervention (n = 279)
Did not receive allocated intervention (n = 19)
No treatment information submitted (n = 4)
Analyzed (n = 300)
  Ineligible (n = 7)
Lost to follow-up (n = 1)
Discontinued intervention early (n = 118)
Adverse event (n = 54)
Treatment related death (n = 5)
Withdrew (n = 27)
Alt therapy (n = 2)
Other disease (n = 5)
Other reason (n = 14)
Unknown (n = 11)
PD or death not due to treatment (n = 161)
Lost to follow-up (n = 1)
Discontinued intervention early (n = 106)
Adverse event (n = 36)
Treatment related death (n = 1)
Withdrew (n = 27)
Alt therapy (n = 2)
Other disease (n = 3)
Other reason (n = 24)
Unknown (n = 13)
PD or death not due to treatment (n = 150)
                   Gemcitabine + placebo
Allocated to intervention (n = 300)
Received allocated intervention (n = 256)
Did not receive allocated intervention (n = 33)
No treatment information submitted (n = 11)
Analyzed (n = 302)
  Ineligible (n = 11)
Fig 1. CONSORT diagram. ITT, intent to
treat; Alt, alternative; PD, progressive disease.
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Abbreviations: ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbo-
hydrate antigen 19-9.
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DSMB released study data. At that point, 300 deaths (159 on the
bevacizumab arm, 141 on the placebo arm) had been reported. Me-
dian OS was 4.99 and 5.45 months for the bevacizumab and placebo
arms, respectively. The HR estimate was 0.90 in favor of placebo with
99.5% CI of 0.65 to 1.23. This interval did not contain the targeted HR
of 1.35. Thus, the futility boundary was met. Since it was considered
unlikely that there would be significant differences in OS between
treatment arms with further follow-up, all patients on treatment were
unblinded and notified of these results. Patients thought to be bene-
fiting from bevacizumab were allowed to continue it with informed
consent. Adverse event monitoring was conducted for any grade  3
bleeding or proteinuria, or grade  4 hypertension. No protocol-
specified boundaries were crossed during interim toxicity monitoring
for these end points. Monitoring for grade  3 thrombosis was con-
ducted separately and was not significantly different between arms at
any interim analysis.
Treatment Administration
A mean of 4.4 cycles of gemcitabine/bevacizumab and 3.9 cycles
of gemcitabine/placebo were administered (P  .02).
Survival and Response
There was no statistically significant difference in median OS
between study arms. The resulting stratified HR was 1.044 for
placebo versus bevacizumab (95% CI, 0.88 to 1.24). The Kaplan-
Meier curves for OS by treatment arm are shown in Figure 2. The
median OS was 5.8 months (95% CI, 4.9 to 6.6) for gemcitabine/
bevacizumab and 5.9 months (95% CI, 5.1 to 6.9) for gemcitabine/
placebo (P  .95).
There were statistically significant differences in survival by ex-
tent of disease and PS. Patients with metastatic disease survived a
median of 5.7 months compared with 9.9 months for patients with
locally advanced disease (P  .009; Fig 3). Patients with a PS of 0
survived a median of 7.9 months compared with 4.8 and 2.4 months
for PS 1 and PS 2 patients, respectively (P  .001; Fig 4). These
differences were consistent between treatment arms.
Figure 5 illustrates the Kaplan-Meier curves for PFS by treatment
arm. The median PFS was 3.8 months (95% CI, 3.4 to 4.0 months) and
2.9 months (95% CI, 2.4 to 3.7 months) for the bevacizumab and
placebo arms, respectively (P  .075).
Objective response rates were not significantly different: 13% for
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Fig 5. Progression-free survival by treatment arm.
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(1% CR, 9% PR). Stable disease occurred in 41% and 34% of patients
on the bevacizumab and placebo arms, respectively.
Adverse Events
Grade 3 and 4 adverse events are summarized in Table 2.
There were 13 treatment-related deaths. Five of the 10 deaths on
the experimental arm were potentially attributable to bevacizumab
(one hemorrhage, two pulmonary embolism, and two perfora-
tions). There were no differences in 30- and 60-day all-cause mor-
tality between treatment arms.
Hematologic adverse events were similar in both groups. Statis-
tically significant differences in nonhematologic events occurred only
for grade  3 hypertension (bevacizumab 10% v placebo 3%;
P  .001) and proteinuria (5% v 1%; P  .002). Although high, rates
of venous thrombosis grade  3 were nearly identical (14% and 15%)
for the bevacizumab and placebo arms, respectively. There were 31
bleeding (grade  3), proteinuria (grade  3), or hypertension
(grade  4) adverse events on the bevacizumab arm and 12 on the
placebo arm (P  .006). This significant difference was principally due
to the differences in proteinuria (15 v two events).
DISCUSSION
This randomized phase III study demonstrates that the addition of
bevacizumab to gemcitabine does not improve survival in advanced
pancreatic cancer patients. Not only does this trial fail to confirm the
results of a prior phase II study of this regimen,13 these data also differ
from the results achieved by the addition of bevacizumab to chemo-
therapy in several other malignancies.18-21 They are, however, similar
to data from other randomized trials of the VEGF inhibtors bevaci-
zumab, axitinib, and aflibercept in this disease.22-24
Patient selection is likely the most important factor in the dispar-
ate results of this phase III CALGB study and the phase II trial that
provided the study rationale. The University of Chicago phase II trial13
reported a PR rate of 21% and a median OS of 8.8 months. The
CALGB considered these results sufficiently promising for evaluation
in a phase III study.
In retrospect, it is clear that the Chicago trial accrued a more fit
population. Although all of the patients had metastatic disease and
83% had liver metastases, both of which augur a poor prognosis, that
trial also contained more patients with a PS of 0, excluded patients
with prior thrombosis, and had more patients who had received adju-
vant therapy.
The striking differences in OS by PS observed in CALGB 80303
highlight the critical importance of this metric in predicting prognosis
in advanced pancreatic cancer patients.25 Median survival was 7.9
months in PS 0 patients, 4.8 months in PS 1 patients, but only 2.4
months in PS 2 patients. It is likely that the 8.8-month median OS in
the Chicago trial is partly attributable to the high proportion of PS 0
patients (60% v 38% in CALGB 80303) rather than to any bevaci-
zumab effect. These data also suggest that future phase III trials eval-
uating new agents in advanced pancreatic cancer should be confined
to patients with PS 0 and 1, since the limited survival of PS 2 patients is
too brief to observe a potential drug effect.
Negative phase III results despite promising single-arm phase II
data are, unfortunately, a common outcome in pancreatic cancer
trials.3-10 These collective data suggest that in this disease, a single-arm,
phase II trial design may not be not optimal.26 If the phase II study of
gemcitabine/bevacizumab had employed a randomized phase II de-
sign, both arms would likely have contained similarly selected patients
and shown little difference in outcome.
The addition of bevacizumab to chemotherapy increases OS
and/or response rates and PFS in colorectal cancer, non–small-cell
lung cancer, and breast cancer.18-21 When CALGB 80303 was initiated, it
was plausible that these results would be replicated in pancreatic
cancer. There are several possible explanations why this did not occur.
By normalizing tumor vasculature, VEGF inhibitors may en-
hance drug delivery, thereby increasing chemotherapy activity.27
Gemcitabine may be the most active agent for pancreatic cancer, but it
is only modestly effective.2 Better delivery of a marginal agent yields
marginal activity.
The preclinical models that suggested that VEGF inhibitors
would be effective in pancreatic cancer28-33 may not replicate the
human tumor microenvironment as well as newer genetically engi-
neered models.34 Similar to human tumors, the dysfunctional vascu-
lature of genetically engineered pancreatic models have a markedly
diminished vessel density embedded in dense stroma, limiting drug
delivery.34 Other potential mechanisms of resistance to VEGF inhibi-
tors have been described.35-37
In conclusion, we have demonstrated that the addition of
bevacizumab to gemcitabine does not improve survival in advanced
pancreatic cancer. Our experience provides a rationale for favoring
randomized phase II screening designs so that differences between the
regimens rather than in the attributes of the study participants distin-
guish the differential impact of alternative treatment strategies.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Although all authors completed the disclosure declaration, the following
author(s) indicated a financial or other interest that is relevant to the subject
matter under consideration in this article. Certain relationships marked
with a “U” are those for which no compensation was received; those
relationships marked with a “C” were compensated. For a detailed
description of the disclosure categories, or for more information about
ASCO’s conflict of interest policy, please refer to the Author Disclosure
Declaration and the Disclosures of Potential Conflicts of Interest section in
Information for Contributors.
Employment or Leadership Position: None Consultant or Advisory
Role: Hedy Lee Kindler, Roche (C), OSI Pharmaceuticals (C); Herbert









Neutropenia 33 29 .35
Anemia 5 8 .22
Thrombocytopenia 12 12 1.0
Bleeding 5 4 .68
Cerebrovascular accident 2 2 1.0
Hypertension 10 3  .001
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